By DERRICK GINGERY

The Congressional Budget Office’s score of the Senate FDA user fee package should please the legislators because while new FDA mandates are expected to increase costs, the net effect of the package is expected to decrease the price of drugs

By ANNA YUKHANANOV

U.S. drug regulators would be able to label such treatments "breakthrough" therapies, and work with companies to speed up clinical trials, for example by testing the drugs for a shorter time or enrolling fewer patients.

The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.